United Therapeutics Corporation
$26.6M 16,575 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
LivaNova USA, Inc.
LivaNova USA, Inc. reported $26,345,998.08 across General Payments, Research, and Ownership to 8,622 physicians and teaching hospitals across 10,999 transactions.
- $26.3M Top 10% payer
- All-tracks total
- 10,999 Top 10% volume
- Transactions
- 8,622 Top quartile reach
- Recipients
- +$1.7M
- General Payments vs PY2023
LivaNova USA, Inc. reported $26,345,998.08 across all CMS Open Payments tracks (General + Research + Ownership) to 8,622 physicians and teaching hospitals in Program Year 2024 - ranking #79 of 1,925 reporting manufacturers (0.2% of the all-tracks industry total); General Payments alone were $19,722,392.74, averaging $3.1K per recipient.
How LivaNova USA, Inc.'s $26.3M all-tracks total breaks down
LivaNova USA, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
A
91/100
Total payments
A
100/100
Transaction volume
A
90/100
Physician reach
C
75/100
Payment type diversity
A
100/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer livanova-usa-inc LivaNova USA, Inc.
$26.3M · #79/1,925 · 0.2% industry · PY2024
- TOT $26.3M
- RANK #79
- SHARE 0.2%
- TXN 10,999
- RCP 8,622
- CAT 9
- GEN $19.7M
- ΔGEN +$1.7M
- TOP1 88.5%
- PY 2024
Volume peers
Nearest volume peer: United Therapeutics Corporation ($26.6M)
LivaNova USA, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
LivaNova USA, Inc.'s CMS-reported General Payments increased by $1.7M (+9.2%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: LIVANOVA USA, INC.PY2023: LIVANOVA USA, INC.PY2024: LivaNova USA, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $18,054,445.49
- PY2024
- $19,722,392.74
What the Data Shows for LivaNova USA, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For LivaNova USA, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
Of the 9 general-payment categories charted below, "Royalty or License" is the largest at $17.5M across 5 transactions, 88.5% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 9 types of general payments, LivaNova USA, Inc.'s largest category was "Royalty or License" at $17.5M - 88.5% of General Payments.
LivaNova USA, Inc. reports 9 general-payment categories - the top three are Royalty or License (88.5%), Compensation for Services Other Than Consulting (4.5%), and Travel and Lodging (2.6%). The remaining 6 categories make up 4.4% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: LivaNova USA, Inc. files across 9 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How LivaNova USA, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Royalty or License | $17.5M | 5 | 88.5% |
| Compensation for Services Other Than Consulting | $893.0K | 449 | 4.5% |
| Travel and Lodging | $503.5K | 1,290 | 2.6% |
| Food and Beverage | $363.3K | 6,756 | 1.8% |
| Debt Forgiveness | $303.6K | 69 | 1.5% |
| Honoraria | $83.0K | 16 | 0.4% |
| Compensation for Faculty or Speaker (Medical Education) | $42.6K | 23 | 0.2% |
| Consulting Fee | $39.3K | 9 | 0.2% |
| Grant | $38.1K | 5 | 0.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $17,967,004.57 (91.1%) of $19,722,392.74 in this company's General Payments records across 3,077 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for LivaNova USA, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Ivan Osorio
$17,456,052.97 across 5 reported transactions
- 2
Ahmed Abdelmoity
$174,428.84 across 219 reported transactions
- 3
Augustus Rush
$169,053.91 across 103 reported transactions
- 4
Danielle Becker
$109,099.51 across 123 reported transactions
- 5
Kathryn a. Polovitz
$58,369.34 across 88 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
LivaNova USA, Inc.'s spend rank (#79 of 1,925, top 4% by spend) and concentration rank (#197 of 1,838, top 11% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Veryan Medical Incorporated : $359.2K total payments, HHI 8362
- Poriferous LLC : $7.6K total payments, HHI 8281
- Myocardial Solutions, Inc. : $4.2K total payments, HHI 8121
- Immucor, Inc. : $601.94 total payments, HHI 8069
- Bridge to Life Ltd : $5.6K total payments, HHI 7946
- Cortigent Inc : $4.9K total payments, HHI 7844
- LivaNova USA, Inc. (this company) : $19.7M total payments, HHI 7836
- Koven Technology, Inc. : $10.6K total payments, HHI 7810
- OVIK Health, LLC : $38.7K total payments, HHI 7808
- Lifescan, Inc. : $114.78 total payments, HHI 7756
- Trevena, Inc. : $59.3K total payments, HHI 7689
- Prenosis Inc. : $144.5K total payments, HHI 7679
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as LivaNova USA, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about LivaNova USA, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with LivaNova USA, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Cardio Flow, Inc.
$26.8M 22 recipients
Compare payment profiles
F. Hoffmann-La Roche AG
$25.8M 1,104 recipients
Compare payment profiles
Henry Schein, Inc.
$27.4M 2,793 recipients
Compare payment profiles
Regeneron Healthcare Solutions, Inc.
$24.7M 169,362 recipients
Compare payment profiles
Siemens Medical Solutions USA, Inc.
$28.1M 10,318 recipients
Compare payment profiles
Put this to use
LivaNova USA, Inc. ranks #79 of 1,925 by all-tracks total payments, led by "Royalty or License".
- See where LivaNova USA, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Royalty or License" spend across every manufacturer, not just LivaNova USA, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.